RBBP9

Summary

RBBP9 (RB binding protein 9, serine hydrolase, HGNC:9892) is a protein-coding gene on chromosome 20p11.23, encoding Serine hydrolase RBBP9 (O75884). Serine hydrolase.

The protein encoded by this gene is a retinoblastoma binding protein that may play a role in the regulation of cell proliferation and differentiation. Two alternatively spliced transcript variants of this gene with identical predicted protein products have been reported, one of which is a nonsense-mediated decay candidate.

Source: NCBI Gene 10741 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 40 total
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_006606

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:9892
Approved symbol	RBBP9
Name	RB binding protein 9, serine hydrolase
Location	20p11.23
Locus type	gene with protein product
Status	Approved
Aliases	Bog
Ensembl gene	ENSG00000089050
Ensembl biotype	protein_coding
OMIM	602908
Entrez	10741

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 2 protein_coding, 2 protein_coding_CDS_not_defined

ENST00000337227, ENST00000491835, ENST00000493184, ENST00000966865

RefSeq mRNA: 1 — MANE Select: NM_006606 NM_006606

CCDS: CCDS13136

Canonical transcript exons

ENST00000337227 — 5 exons

Exon	Start	End
ENSE00000859319	18495838	18495880
ENSE00001252529	18497069	18497225
ENSE00001342801	18486540	18489990
ENSE00003633213	18490395	18490480
ENSE00003651681	18493958	18494063

Expression profiles

Bgee: expression breadth ubiquitous, 257 present calls, max score 88.18.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 15.5671 / max 133.6934, expressed in 1755 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
186543	11.2775	1735
186544	3.1661	1494
186545	1.1235	785

Top tissues by expression

284 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
pigmented layer of retina	UBERON:0001782	88.18	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	87.53	gold quality
adrenal tissue	UBERON:0018303	87.34	gold quality
bronchial epithelial cell	CL:0002328	86.82	gold quality
ventricular zone	UBERON:0003053	85.66	gold quality
upper leg skin	UBERON:0004262	85.46	gold quality
ganglionic eminence	UBERON:0004023	85.23	gold quality
mucosa of paranasal sinus	UBERON:0005030	85.03	gold quality
stromal cell of endometrium	CL:0002255	84.93	gold quality
palpebral conjunctiva	UBERON:0001812	83.03	gold quality
endothelial cell	CL:0000115	82.93	gold quality
right adrenal gland cortex	UBERON:0035827	82.80	gold quality
right adrenal gland	UBERON:0001233	82.55	gold quality
gall bladder	UBERON:0002110	82.51	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	82.48	gold quality
nasal cavity mucosa	UBERON:0001826	82.31	gold quality
islet of Langerhans	UBERON:0000006	82.08	gold quality
left adrenal gland	UBERON:0001234	81.98	gold quality
calcaneal tendon	UBERON:0003701	81.82	gold quality
adrenal gland	UBERON:0002369	81.79	gold quality
seminal vesicle	UBERON:0000998	81.48	gold quality
skin of hip	UBERON:0001554	81.45	gold quality
left adrenal gland cortex	UBERON:0035825	81.44	gold quality
endometrium	UBERON:0001295	81.25	gold quality
adrenal cortex	UBERON:0001235	81.14	gold quality
cortical plate	UBERON:0005343	80.94	gold quality
penis	UBERON:0000989	80.91	gold quality
gingiva	UBERON:0001828	79.95	gold quality
gingival epithelium	UBERON:0001949	79.84	gold quality
thyroid gland	UBERON:0002046	79.83	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.17
E-MTAB-7303	no	85.07

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

152 targeting RBBP9, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-4283	100.00	66.42	2097
HSA-MIR-4425	100.00	67.59	1049
HSA-MIR-4682	100.00	68.89	1258
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-511-3P	99.99	68.85	1467
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-8068	99.98	73.85	2376
HSA-MIR-3692-3P	99.98	70.27	2139
HSA-MIR-3688-3P	99.97	72.02	2834
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-302E	99.96	70.74	2669
HSA-MIR-1468-3P	99.96	72.74	3797
HSA-MIR-559	99.95	72.28	3609
HSA-MIR-548AB	99.95	71.31	3488
HSA-MIR-548J-3P	99.94	72.61	4881
HSA-MIR-548A-5P	99.94	71.27	3482
HSA-MIR-548AD-5P	99.94	71.23	3502

Literature-anchored findings (GeneRIF, showing 7)

• RBBP10 was expressed widely in various human tissues, and the expression level is somewhat higher in tumor tissues than in normal tissues. (PMID:12296629)
• The crystal structure of human RBBP9 has been determined at 1.72 A resolution by the seleno-methionyl single-wavelength anomalous diffraction method. (PMID:19004028)
• identify RBBP9 as a tumor-associated serine hydrolase that displays elevated activity in pancreatic carcinomas. RBBP9 promotes pancreatic carcinogenesis. (PMID:20080647)
• Data identified RBBP4 and RBBP9 as required for maintenance of multiple PS cell types, and both RBBPs were bound to RB in PS cells. (PMID:21689726)
• Structure- function studies of RBBP9 suggest possible routes for novel cancer drug discovery programs. (PMID:21933118)
• blood samples of lateral sclerosis patients were found to have significantly different levels of expression of CyFIP2 and RbBP9 compared to the levels of expression in control subjects. (PMID:22430187)
• Genome-wide siRNA screens identify RBBP9 function as a potential target in Fanconi anaemia-deficient head-and-neck squamous cell carcinoma. (PMID:36639418)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	rbbp9	ENSDARG00000040713
mus_musculus	Rbbp9	ENSMUSG00000027428
rattus_norvegicus	Rbbp9	ENSRNOG00000007972

Protein

Protein identifiers

Serine hydrolase RBBP9 — O75884 (reviewed: O75884)

Alternative names: B5T-overexpressed gene protein, Retinoblastoma-binding protein 10, Retinoblastoma-binding protein 9

All UniProt accessions (1): O75884

UniProt curated annotations — full annotation on UniProt →

Function. Serine hydrolase. Catalyzes the hydrolytic activation of amino acid ester of the antiviral prodrug valacyclovir to its corresponding active drug, acyclovir. May negatively regulate basal or autocrine TGF-beta signaling by suppressing SMAD2-SMAD3 phosphorylation. May play a role in the transformation process due to its capacity to confer resistance to the growth-inhibitory effects of TGF-beta through interaction with RB1 and the subsequent displacement of E2F1.

Subunit / interactions. Interacts with RB1; the interaction disrupts RB1 binding to E2F1. Interacts with RBL1 and RBL2.

Tissue specificity. Expressed at higher levels in tumor tissues such as carcinoma.

Activity regulation. Inhibited by the natural product emetine produced by the ipecac root.

Miscellaneous. Plays a role in maintaining pluripotency in human stem cells in vitro.

Similarity. Belongs to the RBBP9 family.

Isoforms (2)

UniProt ID	Names	Canonical?
O75884-1	1	yes
O75884-2	2

RefSeq proteins (1): NP_006597* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR010662	RBBP9/YdeN	Family
IPR029058	AB_hydrolase_fold	Homologous_superfamily

Pfam: PF06821

Catalyzed reactions (Rhea), 1 shown:

• valacyclovir + H2O = acyclovir + L-valine + H(+) (RHEA:83871)

UniProt features (33 total): strand 8, sequence conflict 7, helix 7, turn 4, active site 3, chain 1, region of interest 1, splice variant 1, mutagenesis site 1

Structure

Experimental structures (PDB)

3 structures.

PDB	Method	Resolution (Å)
9FCR	X-RAY DIFFRACTION	1.37
7OEX	X-RAY DIFFRACTION	1.51
2QS9	X-RAY DIFFRACTION	1.72

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O75884-F1	96.87	0.95

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (3): 75 (charge relay system); 138 (charge relay system); 165 (charge relay system)

Mutagenesis-validated functional residues (1):

Position	Phenotype
75	loss of serine hydrolase activity. fails to block tgf-beta-mediated anti-proliferative signal in tumor cells.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 98 (showing top): GOBP_EPITHELIUM_DEVELOPMENT, GOBP_LUNG_EPITHELIUM_DEVELOPMENT, GOBP_LUNG_CELL_DIFFERENTIATION, GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_UP, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_DN, SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM4, SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_DN, DODD_NASOPHARYNGEAL_CARCINOMA_UP, GOBP_RESPIRATORY_SYSTEM_DEVELOPMENT, IK3_01, chr20p11, ER_Q6_01, SENGUPTA_NASOPHARYNGEAL_CARCINOMA_UP, MIKKELSEN_ES_ICP_WITH_H3K4ME3

GO Biological Process (4): xenobiotic metabolic process (GO:0006805), response to nematode (GO:0009624), positive regulation of gene expression (GO:0010628), type II pneumocyte differentiation (GO:0060510)

GO Molecular Function (3): serine hydrolase activity (GO:0017171), protein binding (GO:0005515), hydrolase activity (GO:0016787)

GO Cellular Component (1): nucleoplasm (GO:0005654)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
metabolic process	1
cellular response to xenobiotic stimulus	1
response to other organism	1
gene expression	1
regulation of gene expression	1
positive regulation of macromolecule biosynthetic process	1
lung secretory cell differentiation	1
hydrolase activity	1
binding	1
catalytic activity	1
nuclear lumen	1
cellular anatomical structure	1

Protein interactions and networks

STRING

588 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
RBBP9	YRDC	Q86U90	895
RBBP9	Q92681	Q92681	710
RBBP9	PPME1	Q9Y570	673
RBBP9	ZNF133	P52736	621
RBBP9	SLC6A2	P23975	550
RBBP9	ABHD17B	Q5VST6	541
RBBP9	BLCAP	P62952	529
RBBP9	CYFIP2	Q96F07	507
RBBP9	SLC22A6	Q4U2R8	497
RBBP9	SLC24A3	Q9HC58	488
RBBP9	LYPLA2	O95372	484
RBBP9	SEC23B	Q15437	475
RBBP9	KAT14	Q9H8E8	463
RBBP9	PREPL	Q4J6C6	459
RBBP9	ABHD17A	Q96GS6	454
RBBP9	BPHL	Q86WA6	454

IntAct

7 interactions, top by confidence:

A	B	Type	Score
RBBP9	RCBTB2	psi-mi:“MI:0915”(physical association)	0.560
TERF2IP	RBBP9	psi-mi:“MI:0915”(physical association)	0.510
GOT1	A2ML1	psi-mi:“MI:0914”(association)	0.350
RBBP9	TERF2IP	psi-mi:“MI:0915”(physical association)	0.000
RBBP9	RCBTB2	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (16): RCBTB2 (Two-hybrid), RBBP9 (Proximity Label-MS), RBBP9 (Proximity Label-MS), RBBP9 (Proximity Label-MS), RBBP9 (Proximity Label-MS), RBBP9 (Affinity Capture-MS), RBBP9 (Two-hybrid), RBBP9 (Affinity Capture-Western), RBBP9 (Affinity Capture-Western), RBBP9 (Affinity Capture-Western), RBBP9 (Affinity Capture-MS), RBBP9 (Affinity Capture-MS), LMNA (Cross-Linking-MS (XL-MS)), RBBP9 (Affinity Capture-RNA), RBBP9 (Two-hybrid)

ESM2 similar proteins: A0PJE2, A4FUZ6, A6QP05, D2WKD9, F1QWW8, O49213, O66148, O75884, O88736, O88851, P13653, P15904, P23591, P30043, P52556, P56658, P56937, Q06136, Q0IH28, Q0VCN1, Q0VFE7, Q13630, Q2KIJ5, Q3T0R4, Q41578, Q42850, Q566S6, Q59987, Q5R6U1, Q5RBE5, Q5RJY4, Q5ZID0, Q62904, Q66KC4, Q67WR2, Q6GV12, Q6IAN0, Q6P5L8, Q6PAY8, Q7XKF3

Diamond homologs: O75884, O88350, O88851

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

40 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	29
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

574 predictions. Top by Δscore:

Variant	Effect	Δscore
20:18490394:CCA:C	donor_gain	1.0000
20:18494065:T:C	acceptor_gain	1.0000
20:18497065:TTAC:T	donor_loss	1.0000
20:18497066:TA:T	donor_loss	1.0000
20:18497067:A:AC	donor_gain	1.0000
20:18497068:C:CC	donor_gain	1.0000
20:18497068:C:CG	donor_loss	1.0000
20:18497068:CCTT:C	donor_gain	1.0000
20:18489872:ATCGG:A	donor_gain	0.9900
20:18489873:T:C	donor_gain	0.9900
20:18489882:T:TA	donor_gain	0.9900
20:18489987:TATC:T	acceptor_gain	0.9900
20:18489989:TC:T	acceptor_gain	0.9900
20:18489990:CC:C	acceptor_gain	0.9900
20:18489991:C:CC	acceptor_gain	0.9900
20:18489992:T:C	acceptor_loss	0.9900
20:18490393:A:AC	donor_gain	0.9900
20:18490394:C:CC	donor_gain	0.9900
20:18490478:TAC:T	acceptor_gain	0.9900
20:18490478:TACC:T	acceptor_loss	0.9900
20:18490482:T:A	acceptor_loss	0.9900
20:18494073:C:CT	acceptor_gain	0.9900
20:18489986:GTATC:G	acceptor_gain	0.9800
20:18490389:ACT:A	donor_loss	0.9800
20:18490391:T:TA	donor_loss	0.9800
20:18490392:TACC:T	donor_gain	0.9800
20:18490393:ACC:A	donor_loss	0.9800
20:18490393:ACCA:A	donor_gain	0.9800
20:18490394:C:CT	donor_loss	0.9800
20:18490394:CCAC:C	donor_gain	0.9800

AlphaMissense

1229 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
20:18493982:C:A	S75I	0.986
20:18489983:G:C	F114L	0.985
20:18489983:G:T	F114L	0.985
20:18489985:A:G	F114L	0.985
20:18497101:A:G	W23R	0.984
20:18497101:A:T	W23R	0.984
20:18490480:C:A	R83S	0.982
20:18490480:C:G	R83S	0.982
20:18494043:A:G	W55R	0.982
20:18494043:A:T	W55R	0.982
20:18489827:A:C	F166L	0.980
20:18489827:A:T	F166L	0.980
20:18489829:A:G	F166L	0.980
20:18493977:C:A	G77W	0.979
20:18497139:A:T	V10D	0.977
20:18489830:G:C	H165Q	0.975
20:18489830:G:T	H165Q	0.975
20:18493976:C:T	G77E	0.975
20:18489973:A:G	W118R	0.973
20:18489973:A:T	W118R	0.973
20:18493976:C:A	G77V	0.973
20:18494032:G:C	F58L	0.973
20:18494032:G:T	F58L	0.973
20:18494034:A:G	F58L	0.973
20:18493964:G:T	A81D	0.972
20:18489944:G:C	C127W	0.971
20:18493958:C:G	R83T	0.971
20:18493981:A:C	S75R	0.970
20:18493981:A:T	S75R	0.970
20:18493983:T:G	S75R	0.970

dbSNP variants (sampled 300 via entrez): RS1000027169 (20:18493291 A>C), RS1000490220 (20:18494608 G>A), RS1000621488 (20:18486457 C>G), RS1000817341 (20:18498320 T>C), RS1000842832 (20:18494273 T>G), RS1000879394 (20:18489707 A>G,T), RS1001030133 (20:18494275 C>T), RS1001363753 (20:18487290 T>C), RS1001425308 (20:18491801 A>G), RS1001544521 (20:18486922 A>C), RS1002115158 (20:18492956 A>G,T), RS1002377379 (20:18492584 C>A), RS1002572320 (20:18493262 G>A), RS1002670614 (20:18499081 A>G), RS1002819452 (20:18495327 T>G)

Disease associations

OMIM: gene MIM:602908 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL1075121 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 22,457 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL50588	EMETINE	4	22,457

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — 3.1.1.- Carboxylic Ester Hydrolases

Most potent curated ligand interactions (1 total), top 1:

Ligand	Action	Affinity	Parameter
Ala(1-naph)-Pro-CN	Inhibition	6.06	pIC50

ChEMBL bioactivities

13 potent at pChembl≥5 of 13 total, top 10 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
6.20	IC50	635	nM	CHEMBL1092791
6.19	IC50	640	nM	CHEMBL1092791
5.92	IC50	1200	nM	CHEMBL1092115
5.82	IC50	1500	nM	CHEMBL1092816
5.72	IC50	1900	nM	CHEMBL1093346
5.30	IC50	5000	nM	CHEMBL1092116
5.24	IC50	5700	nM	CHEMBL1092376
5.11	IC50	7800	nM	EMETINE
5.04	IC50	9200	nM	CHEMBL1092114
5.04	IC50	9100	nM	CHEMBL1092114

PubChem BioAssay actives

8 with measured affinity, of 59 total; 7 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
[(E)-1-(1,3-thiazol-2-yl)ethylideneamino] cyclohexanecarboxylate	475016: Displacement of fluorophosphate-rhodamine from RBBP9 transfected in human HEK293T cells proteomes after 30 mins by SDS-PAGE gel fluorescence assay	ic50	0.6400	uM
[(3,5-dimethyl-4-oxocyclohexa-2,5-dien-1-ylidene)amino] (E)-3-phenylprop-2-enoate	475016: Displacement of fluorophosphate-rhodamine from RBBP9 transfected in human HEK293T cells proteomes after 30 mins by SDS-PAGE gel fluorescence assay	ic50	1.2000	uM
[(3,5-dimethyl-4-oxocyclohexa-2,5-dien-1-ylidene)amino] 4-methoxybenzoate	475016: Displacement of fluorophosphate-rhodamine from RBBP9 transfected in human HEK293T cells proteomes after 30 mins by SDS-PAGE gel fluorescence assay	ic50	1.5000	uM
[(E)-1-(1,3-thiazol-2-yl)ethylideneamino] 4-chlorobenzoate	475016: Displacement of fluorophosphate-rhodamine from RBBP9 transfected in human HEK293T cells proteomes after 30 mins by SDS-PAGE gel fluorescence assay	ic50	1.9000	uM
[(E)-1-(1,3-thiazol-2-yl)ethylideneamino] 4-fluorobenzoate	475016: Displacement of fluorophosphate-rhodamine from RBBP9 transfected in human HEK293T cells proteomes after 30 mins by SDS-PAGE gel fluorescence assay	ic50	5.7000	uM
(2S,3R,11bS)-2-[[(1R)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-1-yl]methyl]-3-ethyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizine	475016: Displacement of fluorophosphate-rhodamine from RBBP9 transfected in human HEK293T cells proteomes after 30 mins by SDS-PAGE gel fluorescence assay	ic50	7.8000	uM
[(E)-1-(1,3-thiazol-2-yl)ethylideneamino] 4-methoxybenzoate	475016: Displacement of fluorophosphate-rhodamine from RBBP9 transfected in human HEK293T cells proteomes after 30 mins by SDS-PAGE gel fluorescence assay	ic50	9.2000	uM

CTD chemical–gene interactions

37 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	affects cotreatment, increases abundance, increases expression, decreases expression	3
Acetaminophen	decreases expression	2
bisphenol F	increases expression	1
triphenyl phosphate	affects expression	1
methylparaben	decreases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
manganese chloride	affects cotreatment, increases abundance, increases expression	1
2,3-bis(3’-hydroxybenzyl)butyrolactone	affects cotreatment, increases expression	1
nickel sulfate	decreases expression	1
torcetrapib	increases expression	1
bisphenol B	increases expression	1
jinfukang	increases expression, affects cotreatment	1
NSC 689534	affects binding, decreases expression	1
bisphenol AF	increases expression	1
Resveratrol	affects cotreatment, increases expression	1
Sunitinib	decreases expression	1
Zoledronic Acid	increases expression	1
Arsenic	increases abundance, increases expression, affects cotreatment	1
Atrazine	decreases expression	1
Benzo(a)pyrene	increases expression	1
Cadmium	increases abundance, decreases expression	1
Cisplatin	affects cotreatment, increases expression	1
Copper	affects binding, decreases expression	1
Coumestrol	affects cotreatment, increases expression	1
Diuron	decreases expression	1
Ivermectin	decreases expression	1
Manganese	affects cotreatment, increases abundance, increases expression	1
Plant Extracts	affects cotreatment, increases expression	1
Thiram	decreases expression	1
Urethane	decreases expression	1

ChEMBL screening assays

9 unique, capped per target: 8 binding, 1 unclassified

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1114312	Binding	Displacement of fluorophosphate-rhodamine from RBBP9 transfected in human HEK293T cells proteomes after 30 mins by SDS-PAGE gel fluorescence assay	Oxime esters as selective, covalent inhibitors of the serine hydrolase retinoblastoma-binding protein 9 (RBBP9). — Bioorg Med Chem Lett
CHEMBL1738515	Unclassified	PUBCHEM_BIOASSAY: Late stage results from the probe development effort to identify inhibitors of Retinoblastoma Binding Protein 9 (RBBP9): Gel-based Activity-Based Protein Profiling (ABPP) IC50. (Class of assay: confirmatory) [Related pubch	PubChem BioAssay data set

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.